As part of the collaboration agreement Open Orphan will include Empiric’s privacy-preserving and artificial intelligence-enabled software in its rare disease database.
Open Orphan intends to “roll up” a number of orphan drug services businesses. It is currently developing the database and owns the Virtual Rep platform, which enables pharma companies to engage key opinion leaders and physicians.
In targeting the arena of orphan drugs, which treat rare diseases and address unmet medical needs, it is tapping into one of the fastest expanding sectors in the drugs industry.
Of the latest announcement, Open Orphan chief executive Cathal Friel said: "This is an exciting step towards the completion of our genomic Health Data platform, and we are delighted to have Empiric on board to help us quickly and securely become one of the largest databases of rare disease patients in Europe."